| Literature DB >> 28588009 |
Lucia Casadei1,2, Federica Calore3, Chad J Creighton4, Michele Guescini5, Kara Batte1,2, O Hans Iwenofu6, Abeba Zewdu1,2, Danielle A Braggio1,2, Kate Lynn Bill1,2, Paolo Fadda3, Francesca Lovat3, Gonzalo Lopez1,2, Pierluigi Gasparini3, James L Chen1,2, Raleigh D Kladney3,7,8, Gustavo Leone3,7,8, Dina Lev9, Carlo M Croce10, Raphael E Pollock11,2.
Abstract
Despite the development of combined modality treatments against liposarcoma in recent years, a significant proportion of patients respond only modestly to such approaches, possibly contributing to local or distant recurrence. Early detection of recurrent or metastatic disease could improve patient prognosis by triggering earlier clinical intervention. However, useful biomarkers for such purposes are lacking. Using both patient plasma samples and cell lines, we demonstrate here that miR-25-3p and miR-92a-3p are secreted by liposarcoma cells through extracellular vesicles and may be useful as potential biomarkers of disease. Both miR-25-3p and miR-92a-3p stimulated secretion of proinflammatory cytokine IL6 from tumor-associated macrophages in a TLR7/8-dependent manner, which in turn promoted liposarcoma cell proliferation, invasion, and metastasis via this interaction with the surrounding microenvironment. Our findings provide novel and previously unreported insight into liposarcoma progression, identifying communication between liposarcoma cells and their microenvironment as a process critically involved in liposarcoma progression. This study establishes the possibility that the pattern of circulating miRNAs may identify recurrence prior to radiological detectability while providing insight into disease outcome and as a possible approach to monitor treatment efficacy. Cancer Res; 77(14); 3846-56. ©2017 AACR. ©2017 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28588009 PMCID: PMC6033276 DOI: 10.1158/0008-5472.CAN-16-2984
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701